Lufthansa boss quits for Roche pharmaceuticals (Update)

Sep 16, 2013 by Simon Morgan

The head of German airline Lufthansa, Christoph Franz, will step down at the end of his current contract in May 2014 to head the board of directors at Roche pharmaceutical group, the companies announced on Monday.

"Christoph Franz has informed Deutsche Lufthansa AG that he is not available for an extension of his contract as chairman of the executive board and CEO," Lufthansa said in a statement.

Switzerland's Roche said in a statement that Franz has been nominated to succeed its chief Franz Humer, who plans to retire early next year.

Roche said Franz would be proposed formally to its shareholders at the group's annual meeting on March 4.

Franz said he was "delighted" to be joining the Basel-based giant.

"Roche is an outstanding company. As a board member I have had ample opportunity to get to know and admire its strong business performance and corporate culture. Strategically, Roche is in very good shape, and I am looking forward to taking on this opportunity."

Humer, a 67-year-old Austrian and Swiss dual citizen, has been with Roche since 1995.

He became chief operating officer in 1998 and chairman in 2001.

Humer lauded 53-year-old Franz, saying that Roche was "getting a chairman with outstanding personal qualities and an impressive record as head of a major global company".

Swiss-based analysts Helvea echoed that, saying Franz's track record was crucial and that "the proposed election looks to be positive for Roche's future".

Franz's intentions to leave Germany's flagship carrier, which he has headed since January 2011, were first reported on Sunday in the Die Welt online edition, which quoted his inner circle. Switzerland's Neue Zuercher Zeiting had meanwhile said he was poised to take over at Roche.

Franz has carved out his career in the transport sector, having moved between Lufthansa and German rail company Deutsche Bahn.

But the German also knows the pharmaceutical sector from serving on Roche's supervisory board since 2011.

He has strong ties with Switzerland, having led the Lufthansa-owned company Swiss International Air Lines from 2004 to 2009, turning around the airline which was crafted from defunct carrier Swissair.

Franz said the decision to leave—after 15 years in the Lufthansa group—was "anything but easy".

"I like working for this company. But for career reasons, I have decided to end my work for the Lufthansa group once my contract expires in May 2014," he said.

By that time, the airline's restructuring programme and key investment decisions "will have laid the foundation for Lufthansa's future success. That is a suitable time for a change in management," he added.

Lufthansa's supervisory board chief Wolfgang Mayrhuber said he "regretted" Franz's decision to quit.

Investors appeared somewhat unnerved over Lufthansa's future after the announcement.

The airline's shares were among the few losers on the blue-chip DAX index on the Frankfurt stock exchange, slipping by 0.25 percent while the overall market was up 1.19 percent.

On Zurich's SMI, Roche's stock rose 0.59 percent while the overall index was up 0.56 percent.

Explore further: Square raises $100 million for $6 billion valuation

add to favorites email to friend print save as pdf

Related Stories

Roche to take over Genentech for $47 billion

Mar 12, 2009

(AP) -- Swiss pharmaceutical giant Roche said Thursday it has agreed to buy California-based Genentech for $46.8 billion in a takeover described as the largest in Swiss corporate history.

Cochrane group skeptical about latest Roche pledges

Mar 07, 2013

(HealthDay)—Following requests from Cochrane researchers, Roche has pledged to release full clinical study reports for Tamiflu, although there appear to be conditions attached, according to correspondence ...

US wants more information from Roche on Illumina bid

Mar 13, 2012

Swiss pharmaceutical group Roche said Tuesday the US Federal Trade Commission had requested additional information on its hostile $5.7-billion (4.2 billion euros) bid for US gene mapper Illumina.

India denies revoking Roche patent, says it lapsed

Aug 06, 2013

India on Monday denied revoking additional patents related to Roche Holding's breast cancer drug Herceptin, saying the Swiss giant failed to follow legal procedures so the applications lapsed.

Recommended for you

German court lifts ban on Uber car pick-up service

11 hours ago

The controversial but popular car pick-up service Uber claimed a victory in Germany on Tuesday when a court threw out an injunction levelled against its operations in Europe's biggest economy.

Oligarch buys Russia's most popular social media (Update)

13 hours ago

A media company owned by Kremlin-friendly oligarch Alisher Usmanov has splashed out $1.5 billion to gain full control of Russia's most popular social network, VKontakte, bringing an end to a months-long dispute ...

User comments : 0